In the KM-plotter database, the OS of patients with TNBC and the BL subtype was shorter in the high WEE1 expression group compared to the low WEE1 expression group, suggesting that WEE1 can be used as a biomarker to predict poor prognosis and guide targeted therapy in TNBC with the BL subtype. The gene discussed is WEE1; the disease is Burkitt lymphoma.